Investor Relations
Friday August 25，2023
2023 Interim Results Earnings Call
Dear Investors:
Hua Medicine (2552.HK) cordially invites you or your representative to attend the conference call for the Company’s 2023 interim results, which will be held 9:00 AM HKT, August 25, 2023 (Friday).
During the conference call, management will provide a review of the Company’s interim financial results in 2023, business updates, as well as address plans for the future.
Details of the earnings call are as follows:
|
|
|
|
Date: |
August 25, 2023 |
|
Time： |
Login starts: 8:45AM HKT |
|
Duration: |
Approximately 50mins (including Q&A session) |
|
Language: |
English |
|
Management: |
Dr. Li Chen, Founder and CEO |
|
Moderator: |
Christopher Lui, China Healthcare Analyst, Jefferies |
|
RSVP: |
Join zoom webinar: |
About Hua Medicine
Hua Medicine is an innovative drug development and commercialization company based in Shanghai, China, focused on developing novel therapies for patients worldwide with unmet medical needs. Based on global resources, Hua Medicine teams up with global high-caliber people to develop breakthrough technologies and products, which contribute a global innovation in diabetes care. As Hua Medicine's cornerstone product (dorzagliatin tablets), targeting the glucose sensor, glucokinase, restores glucose sensitivity in T2D patients and stabilizes the imbalance of blood glucose levels in patients, it has been approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin hydrochloride-tolerated T2D patients. For patients with chronic kidney disease (CKD) and Type 2 diabetes (i.e., diabetes kidney disease), no dose adjustment is required. Hua Medicine will partner with Bayer, a leading global pharmaceutical company, to commercialize HuaTangNing (華堂寧?) in China, benefiting diabetic patients and their families. HuaTangNing (華堂寧?) has also demonstrated its potential of achieving diabetes remission in clinical studies to help millions of diabetic patients around the world.
滬ICP備14036654號(hào)-1
滬公網(wǎng)安備 31011502013809號(hào) Privacy Statement Terms of Use
